FOI 2024-487

1. How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?

Answer: Less than 5*.

1. How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

Answer: We cannot answer how many patients received chemoimmunotherapy as first line treatment but please see below for the individual drug regimens.

1. Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024

·       FCR (fludarabine + cyclophosphamide + rituximab)

·       FR (fludarabine + rituximab)

·       BR (bendamustine + rituximab)

·       Bendamustine monotherapy

·       RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)

·       Obinutuzumab ± chlorambucil

·       Rituximab + chlorambucil

·       Ofatumumab

·       Other – please specify

Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window

Answer:

*As the requested information relates to a very small number of individuals, providing further detail could potentially lead to identification. This would breach their confidentiality.